Business Wire

NY-PHILIP-MORRIS-INTL

27.9.2021 10:05:09 CEST | Business Wire | Press release

Share
PMI Calls for Science-Based Discourse on Smoke-Free Alternatives

Misinformation threatens progress toward a smoke-free future, reveals a new international survey released today by Philip Morris International Inc. (PMI) (NYSE: PM). Well-funded groups continue to promote false narratives and spread confusion even as societal support increases for smoke-free alternatives that are scientifically substantiated to be a better choice for adults than continued smoking.

The survey—fielded among nearly 30,000 adults in 26 countries by independent research firm Povaddo and commissioned by PMI—reveals that too many adult smokers remain unaware that better alternatives to cigarettes exist, are unable to access them, or are confused by false or misleading information that prevents them from making an informed choice.

There is clear public demand for a collective review of the facts and science about smoke-free products. Nearly eight in 10 respondents (79%) agree that adult smokers who would otherwise continue using cigarettes should have access to and accurate information about smoke-free alternatives. This view is shared by 87% of current adult smokers.

“People expect public health bodies and regulators to reach a scientific consensus around innovative smoke-free alternatives and provide adults who smoke with evidence-based information about these products,” said Grégoire Verdeaux, Senior Vice President, External Affairs at PMI. “Misinformation about smoke-free alternatives—often based on opinion—is a persistent issue that is having real-world consequences. Embracing facts, innovative technologies, and science is the shared responsibility of industry, health authorities, and government, and it’s the least we can do to drive positive change for the world. At Philip Morris International, we prioritize transparency as we transform our business to deliver a smoke-free future—inviting policymakers, the scientific community, and NGOs to review and verify our scientific findings. By providing adult smokers science-based information about better alternatives, we can accelerate the decline in smoking rates, helping to end the use of cigarettes once and for all.”

The survey also shows the extent of public confusion surrounding smoke-free products.

  • Nearly half the adults surveyed wrongly believe that e-cigarettes and heated tobacco products are more harmful than or equally harmful as cigarettes (45% and 46%, respectively, for each product category).
  • Asked why they have not considered switching to a better alternative, around a third of smokers surveyed cited lack of information about how these products differ from cigarettes (33%), uncertainty about the science (35%), or having easier access to cigarettes (32%), the most harmful form of tobacco consumption.

Promisingly, the survey findings also demonstrate how accurate information about better alternatives can help smokers to move away from cigarettes.

  • The vast majority (91%) of adult smokers who have switched to a better alternative and stopped smoking confirmed that having accurate information about how these products differ from cigarettes was an important factor in their decision.
  • Of adults who smoke, 63% would be more likely to switch to a better alternative (such as e-cigarettes or heated tobacco products) if they had clarity on how these products differ from cigarettes and the science behind them.

The survey also explores public attitudes toward scientific studies conducted by manufacturers of smoke-free products. A majority of adults surveyed (82%) believe their governments have a responsibility to objectively review and consider scientific evidence about smoke-free alternative products coming from manufacturers such as PMI. Additionally, nearly three quarters (72%) support tobacco companies working with governments, regulators, and public health experts to ensure that smokers have access to and accurate information about smoke-free alternatives.

To review the complete survey findings, visit PMI.com/informedchoice

Povaddo Survey Methodology

Povaddo conducted this online survey on behalf of PMI between July 19 and August 3, 2021. The survey was fielded among 29,484 legal-aged adult respondents, drawn from the general population and aged 21 or older, in 26 countries: Argentina, Brazil, Colombia, Czech Republic, Dominican Republic, France, Greece, Italy, Japan, Malaysia, Mexico, Morocco, Netherlands, Norway, Poland, Portugal, Romania, Saudi Arabia, South Africa, South Korea, Spain, Sweden, United Arab Emirates, Ukraine, the United Kingdom, and the United States.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders, and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2021, PMI’s smoke-free products are available for sale in 67 markets in key cities or nationwide, and PMI estimates that approximately 14.7 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Duna, Built by Stripe Veterans, Raises €30 Million CapitalG-led Series A to Solve Business Identity For The Internet5.2.2026 15:00:00 CET | Press release

Duna, the identity fintech founded by two Stripe alumni, today announced a €30 million Series A funding round led by CapitalG, Alphabet’s independent growth fund. Existing investors Index Ventures, Puzzle Ventures and Snowflake Chairman Frank Slootman also participated in the round. The company, based in Germany and the Netherlands, was launched in 2023 by Duco van Lanschot, who was head of Benelux and DACH at Stripe for three years, and David Schreiber, who spent six years at Stripe where he ran the company’s largest global business unit, including the core card payment platform. In May 2025, the company announced a €10.7 million seed round led by Index Ventures. The latest fundraise brings Duna’s total funding to more than €40 million. Duna’s mission is to build global trust infrastructure by providing a digital passport for every business. Over time, this will evolve into a network for shareable identity and one-click onboarding. Today Duna’s AI-native business identity platform ser

AI-Powered Experian Assistant for Model Risk Management Wins 2026 BIG Innovation Award5.2.2026 15:00:00 CET | Press release

Highlights how Experian’s AI capabilities help global financial institutions keep regulatory documentation aligned with rapid model innovations Experian today announced that its recently launched, AI‑powered Experian Assistant for Model Risk Management has been awarded the 2026 BIG Innovation Award in the Innovative Products category. Recognizing trailblazers across industries since 2014, this global award celebrates exceptional innovation and the value it brings to a recipient’s clients, stakeholders and community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205042051/en/ Experian's recently launched, AI-powered Experian Assistant for Model Risk Management has been awarded the 2026 BIG Innovation Award in the Innovative Products category. Fully integrated into the Experian Ascend Platform™ and powered by ValidMind technology, Experian Assistant for Model Risk Management helps accelerate model validation, improve audit

LTIMindtree Recognized as a Leader in Everest Group Payments IT Services PEAK Matrix® Assessment 20255.2.2026 14:30:00 CET | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, has been positioned as a Leader in the Everest Group Payments IT Services PEAK Matrix® Assessment 2025. This recognition is for being a strategic transformation partner that combines modernization scale, platform alliances, and innovation across real-time, digital assets, and ensure secure, regulator-ready payment environments. Everest Group highlighted LTIMindtree’s strong market impact and vision and capability in delivering largescale payments across issuers, acquirers, payment processors, card networks, and FinTechs. The assessment comes at a time when enterprises are rapidly modernizing legacy payments platforms to support real-time, cross-border, and ISO 20022 compliant payment environments, while enhancing resiliency, interoperability, and regulatory compliance. LTIMindtree stands out for its product engineering expertise across major payment platforms like Finastra GPP/P

PubNub Achieves SOC 3 Compliance, Reinforcing Commitment to Security, Trust, and Transparency5.2.2026 14:00:00 CET | Press release

PubNub, the real-time communications platform that powers low-latency, event-driven logic across modern application architectures, is pleased to announce that it has achieved SOC 3 compliance. This latest attestation highlights PubNub’s continuous dedication to providing a secure and trusted platform for building and scaling interactive online experiences. The SOC 3 report affirms that PubNub’s systems meet the Trust Services Criteria for security, availability, and confidentiality. Unlike SOC 2 reports, which are restricted to existing customers or partners due to the level of operational detail they include, SOC 3 reports are designed for broad, public distribution. This transparency enables anyone to verify that PubNub adheres to the stringent controls required by the SOC 2 framework, providing proof of robust information security and operational integrity. This achievement adds to PubNub’s extensive compliance portfolio, which includes SOC 2 Type 2, ISO/IEC 27001:2022, HIPAA, and G

Visby Medical Collaborates with Watchmaker Genomics to Enhance Respiratory Pathogen Detection in the At-Home Setting5.2.2026 14:00:00 CET | Press release

Visby Medical, a leading innovator in at-home PCR testing of infectious diseases, has announced a strategic collaboration with Watchmaker Genomics, a supplier of innovative products for molecular analysis, to develop next-generation diagnostic tests for respiratory pathogen detection in the at-home setting. This partnership pairs Visby Medical’s instrument-free PCR testing technology – the first and only of its kind – with Watchmaker’s expertise in engineering enzymes to address application-specific performance gaps. Clinical samples collected from patients for at-home testing are typically unprocessed, making them vulnerable to molecular inhibitors that can reduce signal strength and lower assay sensitivity. The need for rapid results in the at-home setting also places unique performance demands on the assays and the enzymes they rely on. “Recent increases in COVID cases involving new strains and the current flu season highlight the need for tests that are reliable and fast,” explaine

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye